Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-03-18
1998-04-07
Kight, John
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514579, 514588, 536 2714, 536 278, A61K 3170
Patent
active
057365270
ABSTRACT:
A method and composition for inhibiting the spread of a retrovirus such as HIV in a human cell population in which a retrovirus such as HIV is present has been found. The spread of the retrovirus is inhibited by treatment of the cells with a synergistic combination mixture of a dideoxy-ribonucleoside excluding AZT and hydroxycarbamide.
REFERENCES:
patent: 4708818 (1987-11-01), Montagnier et al.
patent: 5026687 (1991-06-01), Yarchoan et al.
patent: 5110600 (1992-05-01), Green
patent: 5300059 (1994-04-01), Rubinstein et al.
patent: 5521161 (1996-05-01), Malley et al.
Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication, by Gao et al.; Proc. Natl. Acad. Sci., USA, vol. 90, pp. 8925-8928, Oct. 1993 Medical Sciences.
Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus-Type 1 Replication, by Franco Lori, et al. Science, vol. 266:801-805, Nov., 1994.
The Anti-HTLV-III (Anti-HIV) and Cytotoxic Activity of 2', 3'-Didehydro-2'3'-dideoxyribonucleosides: A Comparison with Their Parental 2',3'-Dideoxyribonucleosides by Jan Balzarini et al., Molecular Pharmacology, 32:162-167 (1987).
AIDS Is More Than HIV: Part 1, by Robert S. Root-Bernstein, Ph.D., Genetic Engineering News pp. 4-6, Sep., 1992.
AIDS Is More Than HIV: Part II, by Robert S. Root-Bernstein, Ph.D., Genetic Engineering News pp. 4-5, Sep., 1992.
Effects of Hydroxyurea and Thymidine Derivatives on the Uptake and Metabolism of Deoxycytidine and Arabinofuranosylcytosine in Log Phase and Contact-Inhibited Human Diploid Fibroblasts by D. Snyder et al., Molecular Pharmacology, 28:574-580 (1985).
Prevention of activation of HIV-1 by antiviral agents in OM-10.1 cells, by P. M. Feorino et al., Antiviral Chemistry & Chemotherapy (1993) 4(1), 55-63.
Inhibition Of Polymerases -.alpha.And .beta.Completely Blocks DNA Repair Induced By UV Irradiation In Cultured Mouse Neronal Cells, by Federico Licastro et al., Biochemical and Biophysical Research Communications, pp. 929-933, v. 132(3), 1985.
Cellular Pharmacology and Anti-HIV Activity of 2', 3'-Dideoxyguanosine by M.E. Busso et al., Aids Research and Human Retroviruses, vol. 6, Nov., 1990, pp. 1139-1146.
Acid-Stable 2'-Fluoro Purine Dideoxynucleosides as Active Agents against HIV, by Victor E. Marquez et al., J. Med. Cm. 1990, 33, pp. 978-985.
The Human Immunodeficiency Virus: Infectivity and Mechanisms of Pathogenes, by Anthony S. Fauci, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Science vol. 239, Feb., 1988, pp. 617-622.
Kaposi's Sarcoma and Pheumocystis Pneumonia Among Homosexual Men--New York City and California, Center For Disease Control, Morbidity and Mortality Weekly Report, U.S. Dept. of Health and Human Services; Jul. 3, 1981/vol. 30/No. 25, pp. 305-308.
Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds, by Serge D. Malley et al., The Lancet (Reprinted from The Lancet Saturday 21 May 1994) vol. 343 No. 9808 p. 1292.
Quiescent T Lymphocytes as an Inducible Virus Reservoir in HIV-1 Infection, by Bukrinsky et al., Science, vol. 254, Mar, 1991, pp. 423-427.
The Reservoir for HIV-1 in Human Peripheral Blood Is a T Cell That Maintains Expression of CD4, by Steven M. Schnittman et al., Science, vol. 245, Jan., 1989, pp. 305-308.
Lymphoid Germinal Centers Are Reservoirs of Human Immunodeficiencty Virus Type 1 RNA, by Cecil H. Fox et al., Journal of Infections Diseases 1991:164; 1051-1057.
The accumulation of DNA breaks due to incision; comparative studies with various inhibitors, Snyder et al., IRL Press Limited, Oxf, England. 13-33.
Multifactorial Nature of Human Immunodeficiency Virus Disease: Implications for Therapy, by Anthony S. Fauci, Science vol. 262, , Nov., 1993, pp. 1011-1018.
HIV-1 Entry into Quiescent Primary Lymphocytes: Molecular Analysis Reveals a Labile, Latent Viral Structure, by Jerome A. Zack et al., Cell, vol. 61, 213-222. Apr., 1990.
Therapy For Human Immunodeficiency Virus Infection, by Martin S. Hirsch et al., The New England Journal of Medicine, Jun., 1993, vol. 329, No. 23, pp. 1686-1696.
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds, by Rudi Pauwels et al., Journal of Virological Methods, 20 (1988) 309-321.
Clinical Pharmacology Of 3'-Azido-2', 3'-Dideoxythymidine (Zidovudine) And Related Dideoxynucleosides, by Robert Yarchoan et al., The New England Journal of Medicine, vol. 321, No. 11, pp. 726-738 (1989).
Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy, by Yung-Kang Chow et al., Nature, 361, 650-654 (18 Feb. 1993).
Hydroxyurea increases the phosphorylation of 3'-fluorothymidine and 3'-zidothymidine in CEM cells, by Anna Karlsson et al., Eur J. Biochem. 186, 689-694 (1989).
Meyerhans et al., "The Intracellular Nucleotide Pool Effects HIV Replication", VIII International Conference on AIDS/III STD World Congress, vol. 2, Jul. 1992, pp. A22-2118.
T'Ang et al., "Optimization of the Schiff Bases of N-Hydroxy-N'aminoguanidine as Anticancer and Antiviral Agents", J. Med. Chem., vol. 28, 1985, pp. 1103-1106.
Lien, "Ribonucleotide reductase inhibitors as anticancer and antiviral agents", Progress in Drug Research, vol. 31, 1987, pp. 101-126.
Lori et al., "Hydroxyurea Inhibits HIV-1 Replication by AP Inducing Low dNTP Levels. A Cellular Enzyme as a Target to Inhibit HIV-1", Antiviral Res., vol. 23/Sup. 1, 1994, p. 63.
Gao et al., "Anti-HIV-1 Activity of Hydroxyurea in Combination with 2',3'-dideoxynucleosides", Clinical Research, vol. 42, No. 2, 1994, p. 280A.
Matsumoto et al., "Inhibition of RNA Synthesis by Deoxyadenosine Plus Deoxycoformycin in Resting Lymphocytes", The Journal of Immunology, vol.131, 1983, pp. 2762-2766.
Gao et al., "Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immuno-deficiency virus type 1 replication", Proc. Natl. Acad. Sci. USA, vol. 90, Oct. 1993, pp. 8925-8928.
Fischl, "Treatment of HIV Disease in 1993/1994", AIDS Clin. Rev., vol. 94, 1993, pp. 167-187.
International Search Report for Internation Application No. PCT/US 94/05515.
Balzarini et al., "2', 3'-Dideoxycytidine: Regulation of its Metabolism and Anti-retroviral Potency by Natural Pyrimidine Nucleosides and by Inhibitors of Pyrimidine Nucleotide Synthesis", Molecular Pharmacology, vol. 32, 1987, pp. 798-806.
Safrin et al., "Potential for Combined Therapy with 348U87, a Ribonucleotide Reductase Inhibitor, and Acyclovir as Treatment for Acyclovir-Resistant Herpes Simplex Virus Infection", Journal of Medical Virology Supplement 1, 1993, pp. 146-149.
Wilson et al., "Purinogenic Immunodeficiency Diseases--Differential Effects of Deoxyadenosine and Deoxyguanosine on DNA Synthesis in Human T Lymphoblasts", J. Clin. Invest., vol. 64, 1979, pp. 1475-1484.
Albert et al., "Deoxyadenosine Toxicity and Cell Cycle Arrest in Hydroxyurea-Resistant S49 T-Lymphoma Cells", Experimental Cell Research, vol. 179, 1988, pp. 417-428.
Ganciclovir Antagonizes the Anit-Human Immunodeficiency Virus Type 1 Activity of Zidovudine and Didanosine In Vitro, by Media et al.; Antimicrobial Agents and Chemotherapy, May 1992, pp. 1127-1130, vol. 36, No. 5.
Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2', 3'-dideoxyinosine in infected resting human lymphocytes, by Malley et al., Proc. Natl. Acad. Sci USA vol. 91, pp. 11017-11021, Nov. 1994, Medical Sciences.
Perno et al., "Inhibition of Human Immunodeficiency Virus AY (HIV-1/HTLV-III.sub.Ba-L ) Replication in Fresh and Cultured Human Peripheral Blood Monocytes/Macrophages by Azidothymidine and Related 2',3'-Dideoxynucleosides", J. of Exp. Medicine, vol. 168, 1988, pp. 1111-1125.
Biron et al., "Anti-HIV Activity of the Combination of Didanosine and Hydroxyurea in HIV-1-Infected Individuals," J. Acquired Immune Deficiency Syndromes and Human Retrovirology, 10, 36-40 (1995).
Barre-Sinoussi et al., "Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)," Science, 220
Malley Serge D.
Vila Jorge R.
Compagnie de Developpment Aguettant S.A.
Crane L. Eric
Kight John
LandOfFree
Method of treating HIV in humans by administration of ddI and hy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating HIV in humans by administration of ddI and hy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating HIV in humans by administration of ddI and hy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-13632